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Abstract
Different clones, protocol conditions, instruments, and scoring/readout methods may pose challenges in introducing different
PD-L1 assays for immunotherapy. The diagnostic accuracy of using different PD-L1 assays interchangeably for various
purposes is unknown. The primary objective of this meta-analysis was to address PD-L1 assay interchangeability based on
assay diagnostic accuracy for established clinical uses/purposes. A systematic search of the MEDLINE database using
PubMed platform was conducted using “PD-L1” as a search term for 01/01/2015 to 31/08/2018, with limitations “English”
and “human”. 2,515 abstracts were reviewed to select for original contributions only. 57 studies on comparison of two or
more PD-L1 assays were fully reviewed. 22 publications were selected for meta-analysis. Additional data were requested
from authors of 20/22 studies in order to enable the meta-analysis. Modified GRADE and QUADAS-2 criteria were used for
grading published evidence and designing data abstraction templates for extraction by reviewers. PRISMA was used to
guide reporting of systematic review and meta-analysis and STARD 2015 for reporting diagnostic accuracy study. CLSI
EP12-A2 was used to guide test comparisons. Data were pooled using random-effects model. The main outcome measure
was diagnostic accuracy of various PD-L1 assays. The 22 included studies provided 376 2×2 contingency tables for
analyses. Results of our study suggest that, when the testing laboratory is not able to use an Food and Drug Administration-
approved companion diagnostic(s) for PD-L1 assessment for its specific clinical purpose(s), it is better to develop a properly
validated laboratory developed test for the same purpose(s) as the original PD-L1 Food and Drug Administration-approved
immunohistochemistry companion diagnostic, than to replace the original PD-L1 Food and Drug Administration-approved
immunohistochemistry companion diagnostic with a another PD-L1 Food and Drug Administration-approved companion
diagnostic that was developed for a different purpose.
Introduction
Clinical trials have shown that it is possible to success-
fully restore host immunity against various malignant
neoplasms even in advanced stage disease by deploying
drugs that target the PD-1/PD-L1 axis [1–5]. In most of
these studies, higher expression of PD-L1 was associated
with a more robust clinical response, suggesting
that detection of PD-L1 expression could be used as
predictive biomarker. However, anti-PD1/PD-L1 therapy
companies developed distinct immunohistochemistry
protocols for assessing a single biomarker (PD-L1
expression), as well as different scoring schemes for the
readouts. The latter include differences in the cell type
assessed for the expression and different cut-off points as
thresholds [2–4]. “Intended use” in this context is a part of
the so-called “3D” concept, where a “fit-for-purpose”
approach to test development and validation establishes
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explicit links between Disease, Drug, and Diagnostic
assay [6].
Several such fit-for-purpose immunohistochemistry kits
are commercially available, but in clinical practice, and
especially in publicly funded health care, it is challenging to
make all such testing available to patients [7–9]. Because of
the great need to simplify testing, either by reducing the
number of immunohistochemistry assays being used or the
number of interpretative schemes employed or both, many
studies have been conducted that compared the analytical
performance of the various immunohistochemistry PD-L1
assays to determine if they might be deemed “inter-
changeable”. The concordance in the analytical perfor-
mance of the immunohistochemistry assays and scoring
algorithms derived from these studies have been reviewed
by Büttner et al. and Udall et al. respectively [7, 10].
Although most of these studies have compared different
PD-L1 immunohistochemistry assays to one another, there
is little guidance on how the results of these studies may be
applied clinically.
The goal of this study is to assess the performance of PD-
L1 immunohistochemistry assays based on their diagnostic
accuracy at specific cut-points, as defined for specific
immunotherapies according to the clinical efficacy demon-
strated in their respective pivotal clinical trials.
In other words, given an Food add Drug Administration-
cleared assay, which other assays can be considered sub-
stantially equivalent for that specific purpose? Although
comparison of immunohistochemistry assays for their ana-
lytical similarities is warranted and useful for clinical
immunohistochemistry laboratories, it is an insufficient
foundation on which to make an informed decision whether
an Food and Drug Administration-approved companion
diagnostic with a specific clinical purpose can be replaced
by another assay, whether the substitute assay is an Food
and Drug Administration-approved companion diagnostic
for a different purpose or a laboratory developed test. The
more appropriate approach for these qualitative assays
would be comparing the results of the candidate assay for its
diagnostic accuracy against a comparative method/assay or
designated reference standard [11]. We report here the
results of our meta-analyses of 376 assay comparisons from
22 studies for different cut-off points, focusing on the
sensitivity and specificity of these tests, based on their
intended clinical utility.
Methods
Methodology including data sources, study selection, data
abstraction, and grading evidence, are detailed in Supple-
mentary Files Methodology. Modified GRADE and
QUADAS-2 criteria were used for grading published
evidence and designing data abstraction templates to guide
independent extraction by multiple reviewers [12–15].
PRISMA was used to guide reporting of the systematic
review and meta-analysis and STARD 2015 for reporting
the diagnostic accuracy study [16–18]. CLSI EP12-A2 was
used to guide test comparisons [11] Data were pooled using
a random-effects model.
Framework
A systematic review of literature was conducted as a part of
a national project for developing Canadian guidelines for
PD-L1 testing. The Canadian Association of Pathologists –
Association canadienne des pathologistes (CAP-ACP)
National Standards Committee for High Complexity Test-
ing initiated development of CAP-ACP Guidelines for PD-
L1 testing to facilitate introduction of PD-L1 testing for
various purposes to Canadian clinical immunohistochem-
istry laboratories. This review was also used to guide the
selection of publications to be used in this meta-analysis.
Purpose-based approach
The purposes identified in the systematic review of pub-
lished literature were based on either the clinical purpose
that was specifically identified in the published study or the
intended purpose for which the included specific companion
diagnostic assay was clinically validated. Although a large
number of potential purposes were identified, only few
could be included in this meta-analysis. The selection was
based on the type of data available, including which
immunohistochemistry protocols and which readout was
performed by the authors. The greatest limitation in the
accrual of data from these published studies was based on
the selection of the readout employed to assess the results;
in most studies the readout was limited to tumor proportion
score with 1% and 50% cut-offs, which is essentially based
on the clinically meaningful cut-offs for pembrolizumab
and nivolumab therapy. Hence, these two readouts were
selected for our analysis and form the basis for outlining
different purposes that are derived from the combination of
the readouts and immunohistochemistry kits/protocols that
use these readouts and are approved by regulatory agencies
(e.g., Food and Drug Administration) for different
clinical uses.
Most published studies on PD-L1 test comparison did
not include 2 × 2 tables that would allow calculations of
either diagnostic sensitivity and specificity or positive per-
cent agreement and negative percent agreement. The CAP-
ACP National Standards Committee for High Complexity
Testing requested this information from the authors of
studies where it was evident that the authors generated such
results, but did not include them in their published
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manuscript. Most studies required generation of multiple
2 × 2 tables, as each one was designed for a specific purpose
and set of candidate’ and ‘comparator’ assays. For primary
studies that provided sufficient detail, information on study
setting, comparative method/reference standard and 2 x 2
tables for different tumor proportion score cut-offs were
extracted, from which accuracy results were reported. Stu-
dies of PD-L1 immunohistochemistry assay comparisons
that did not compare the performance of the assay to any
designated or potential reference standard (e.g., where
analytical comparison of PD-L1 assays were all laboratory
developed tests and/or no specific purpose was identified or
where positive percent agreement and negative percent
agreement could not be generated from study data) [19–22]
were not included in this meta-analysis, because in such
studies, diagnostic accuracy for a specific clinical purpose
could not be determined. The acquisition of data resulted in
cumulative evidence of 376 assay comparisons from 22
published studies [6, 23–43].
Study tissue model(s)
Most studies evaluated PD-L1 immunohistochemistry in
non-small cell lung cancer, resulting in 337 test compar-
isons. Comparisons of test performance in other tumors
were much less common. These included analysis of uro-
thelial carcinoma (20 test comparisons), mesothelioma (9
test comparisons) and thymic carcinoma (9 test
comparisons).
Meta-analysis
Reported or calculated diagnostic accuracy (sensitivity
and specificity) from the individual studies were sum-
marized. Random-effects models were fitted [44, 45]. For
the qualitative review, a forest plot was used to obtain an
overview of sensitivity and specificity for each study.
Cochran’s heterogeneity statistics Q and I2 were used to
examine heterogeneity among studies. Funnel plots and
Egger’s test were applied to detect possible publication
bias (see Supplementary Files for images of funnel plots)
[46, 47]. The significance level of 0.05 was set for all
analyses. Meta-analysis was performed using software
Strata 15 SE.
Interpretation of results
Clinically acceptable diagnostic accuracy
For the purpose of this study, the immunohistochemistry
candidate assays were considered to be acceptable for
clinical applications if both sensitivity and specificity for the
stated clinical purpose/application were ≥90% [48].
Applicability of meta-analysis results: Food and Drug
Administrtion-approved immunohistochemistry kits vs.
laboratory developed tests
Assuming that laboratories follow the instructions for use
provided with Food and Drug Administration-approved or
European CE-marked immunohistochemistry kits, the
overall results of this meta-analysis could be considered
highly representative and generalizable of Food and Drug
Administration-approved assay performance and the
diagnostic accuracy of that assay against a designated
reference standard for the stated specific purpose in any
laboratory. However, this assumption cannot be applied to
the results of laboratory developed tests, because labora-
tory developed test immunohistochemistry protocol con-
ditions were often different in different laboratories
even when the same primary antibody was used, and the
protocol was performed on the same automated instru-
ment with the same detection system (e.g., different
type and duration of antigen retrieval, primary antibody
dilution or incubation time, number of steps of amplifi-
cation, etc.). When the results of the meta-analysis for
laboratory developed tests were suboptimal, but one or
more laboratories achieved ≥90% sensitivity and specifi-
city; we cannot exclude the possibility that with appro-
priate immunohistochemistry protocol modification and
assay validation, other laboratories could also achieve
optimal results. This contrasts with the use of Food
and Drug Administration-approved assays, where no
protocol modifications are allowed. Therefore, where the
results of laboratory developed tests are excellent, they
are representative of what could be achieved by laboratory
developed tests rather than that they are generalizable
and that they will automatically be achieved in all
laboratories.
Results
Meta-analysis (all tissue models)
The number of studies comparing different assays in this
meta-analysis was larger than the number of published
manuscripts, due to the frequent inclusion of multiple test
comparisons in single publication as well as use of different
cut-off points for “positive” vs. “negative” test result.
Table 1A (non-small cell lung cancer), 1B (all tissue types),
2, and 3 summarize the number of studies that included both
candidate and comparator test for a specific, clinically
relevant purpose/cut-off point for a specific tissue model.
Figures 1–13 illustrate forest plots with all studies using
non-small cell lung cancer as tissue model (see Supple-
mentary files for Figures 2–13). There was no significant
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difference in the results when non-small cell lung cancer
studies were analyzed separately vs. meta-analysis of all
tissue models (compare Table 1A to Table 1B).
Cochran’s heterogeneity statistic Q and I2 for sensitivity
and specificity across all studies are shown in Supplemen-
tary Files Table 1.
Non-converging data
Where the number of studies was less than four or when the
data were sparse due to the presence of a zero result in con-
tingency tables (e.g., where sensitivity or specificity was
100%), the models did not converge and did not allow for
Table 1A Summary of NSCLC results from all studies (combined estimate of sensitivity and specificity)
TPS Cut-off Gold Standard Candidate Assay No. of Comparisons Sensitivity (95% CI) Specificity (95% CI)
1% PD-L1 IHC 22C3 pharmDx 22C3 LDT 11 0.99 (0.91–1.00) 1.00 (0.78–1.00)
PD-L1 IHC 28-8 pharmDx 18 0.96 (0.93–0.98) 0.84 (0.77–0.88)
Ventana PD-L1 (SP263) 15 0.93 (0.90–0.96) 0.82 (0.78–0.86)
E1L3N LDT 13 0.84 (0.78–0.89) 0.92 (0.87–0.95)
Ventana PD-L1 (SP142) 17 0.60 (0.53–0.66) 0.96 (0.93–0.98)
28-8 LDT 6 See Table B
SP142 LDT 3 See Table C
SP263 LDT 2 See Table C
73-10 Assay 1 See Table C
PD-L1 IHC 28-8 pharmDx Ventana PD-L1 (SP263) 13 0.91 (0.87–0.94) 0.87 (0.80–0.92)
PD-L1 IHC 22C3 pharmDx 21 0.88 (0.84–0.92) 0.93 (0.91–0.95)
28-8 LDT 4 0.82 (0.67–0.91) 0.91 (0.82- 0.96)
E1L3N LDT 11 0.81 (0.77–0.85) 0.96 (0.89–0.99)
Ventana PD-L1 (SP142) 12 0.57 (0.50–0.64) 0.99 (0.89–1.00)
SP142 LDT 2 See Table C
SP263 LDT 2 See Table C
73-10 Assay 1 See Table C
Ventana PD-L1 (SP263) PD-L1 IHC 28–8 pharmDx 13 0.93 (0.86–0.97) 0.84 (0.79–0.88)
PD-L1 IHC 22C3 pharmDx 16 0.84 (0.77–0.89) 0.91 (0.85–0.94)
E1L3N LDT 8 0.81 (0.75–0.86) 0.93 (0.85–0.96)
Ventana PD-L1 (SP142) 12 0.57 (0.49–0.64) 0.98 (0.97–0.99)
28–8 LDT 4 See Table B
SP142 LDT 1 See Table C
73-10 Assay 1 See Table C
22C3 LDT 1 See Table C
50% PD-L1 IHC 22C3 pharmDx 22C3 LDT 10 See Table B
PD-L1 IHC 28-8 pharmDx 18 0.94 (0.88–0.97) 0.95 (0.92–0.97)
28-8 LDT 6 0.95 (0.81–0.99) 0.76 (0.67–0.83)
Ventana PD-L1 (SP263) 15 0.91 (0.83–0.95) 0.92 (0.89–0.95)
E1L3N LDT 13 0.76 (0.62–0.86) 0.97 (0.95–0.99)
Ventana PD-L1 (SP142) 16 0.41 (0.29–0.53) 1.00 (0.99–1.00)
SP142 LDT 3 See Table C
SP263 LDT 1 See Table C
73-10 Assay 1 See Table C
Ventana PD-L1 (SP263) 28-8 LDT 4 See Table B
PD-L1 IHC 28-8 pharmDx 12 0.68 (0.54–0.79) 0.98 (0.97–0.99)
PD-L1 IHC 22C3 pharmDx 16 0.57 (0.45–0.69) 0.99 (0.97–1.00)
Ventana PD-L1 (SP142) 10 See Table B
SP142 LDT 1 See Table C
22C3 LDT 1 See Table C
73-10 Assay 1 See Table C
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meta-analysis calculations. As summarized in Tables 2 and 3,
the latter occurred in a number of studies that had excellent
results for both sensitivity and specificity (e.g., 22C3
laboratory developed test compared to PD-L1 IHC 22C3
pharmDx) or specificity only (e.g., Ventana PD-L1 (SP142)
compared to Ventana PD-L1 (SP263) and other assays).
Table 1B Summary of results from all studies (combined estimate of sensitivity and specificity)
TPS Cut-off Gold Standard Candidate Assay No. of Comparisons Sensitivity (95% CI) Specificity (95% CI)
1% PD-L1 IHC 22C3 pharmDx 22C3 LDT 11 0.99 (0.91 -1.00) 1.00 (0.78–1.00)
PD-L1 IHC 28-8 pharmDx 21 0.96 (0.92–0.97) 0.84 (0.78–0.88)
Ventana PD-L1 (SP263) 16 0.93 (0.88–0.95) 0.83 (0.77–0.86)
E1L3N LDT 14 0.84 (0.78–0.88) 0.94 (0.90–0.96)
Ventana PD-L1 (SP142) 18 0.61 (0.55–0.67) 0.97 (0.94–0.98)
28-8 LDT 6 See Table B
SP142 LDT 3 See Table C
SP263 LDT 2 See Table C
73-10 Assay 1 See Table C
PD-L1 IHC 28-8 pharmDx Ventana PD-L1 (SP263) 14 0.90 (0.86–0.94) 0.88 (0.82–0.93)
PD-L1 IHC 22C3 pharmDx 24 0.88 (0.84–0.91) 0.94 (0.92–0.96)
28-8 LDT 4 0.82(0.67–0.91) 0.91 (0.82–0.96)
E1L3N LDT 12 0.80 (0.76–0.84) 0.99 (0.94–0.99)
Ventana PD-L1 (SP142) 13 0.59 (0.52–0.66) 0.99 (0.96–1.00)
SP142 LDT 2 See Table C
SP263 LDT 2 See Table C
73-10 Assay 1 See Table C
Ventana PD-L1 (SP263) PD-L1 IHC 28-8 pharmDx 14 0.93 (0.86–0.96) 0.85 (0.80–0.88)
PD-L1 IHC 22C3 pharmDx 17 0.83 (0.76–0.89) 0.91 (0.85–0.94)
E1L3N LDT 9 0.78 (0.71–0.84) 0.93 (0.88–0.96)
Ventana PD-L1 (SP142) 13 0.58 (0.51–0.66) 0.98 (0.96–0.99)
28-8 LDT 4 See Table B
SP142 LDT 1 See Table C
73-10 Assay 1 See Table C
22C3 LDT 1 See Table C
50% PD-L1 IHC 22C3 pharmDx 22C3 LDT 10 See Table B
PD-L1 IHC 28-8 pharmDx 21 0.94 (0.88–0.97) 0.95 (0.93–0.97)
28-8 LDT 6 0.95 (0.81–0.99) 0.76 (0.67–0.83)
Ventana PD-L1 (SP263) 16 0.92 (0.84–0.96) 0.92 (0.90–0.94)
E1L3N LDT 13 0.76 (0.62–0.86) 0.97 (0.95–0.99)
Ventana PD-L1 (SP142) 17 0.42 (0.31–0.54) 1.00 (0.99–1.00)
SP142 LDT 3 See Table C
SP263 LDT 1 See Table C
73-10 Assay 1 See Table C
Ventana PD-L1 (SP263) 28-8 LDT 4 See Table B
PD-L1 IHC 28-8 pharmDx 13 0.69 (0.56–0.79) 0.98 (0.96–0.99)
PD-L1 IHC 22C3 pharmDx 17 0.57 (0.46–0.68) 0.99 (0.98–1.00)
E1L3N LDT 9 0.36 (0.28–0.44) 0.99 (0.93–1.00)
Ventana PD-L1 (SP142) 10 See Table B
SP142 LDT 1 See Table C
22C3 LDT 1 See Table C
73-10 Assay 1 See Table C
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PD-L1 IHC 22C3 pharmDx as reference standard
The highest diagnostic accuracy was shown for well-designed
22C3 laboratory developed tests compared to PD-L1 IHC
pharmDx 22C3. The sensitivity and specificity were both
100% in 8/9 assays for the 50% tumor proportion score cut-
off point (Table 2). The results were almost identical, and
only slightly less robust for the 1% cut-off (Fig. 1a, Table 2).
Both PD-L1 IHC 28-8 pharmDx and Ventana PD-L1 (SP263)
showed acceptable diagnostic accuracy for the 50% cut-off,
but both had <90% specificity against the 1% tumor pro-
portion score cut-off (Fig. 1b–e, Table 1).
No other candidate assays reached 90% sensitivity and
specificity in the meta-analysis for either the 50% or the 1%
Table 2 Sensitivity and specificity of individual studies for which meta-analysis was not performed because of non-converging data
TPS Cut-
off
Gold Standard Assay Candidate Assay Author Year Tumor Type* Sample Size Sensitivity Specificity
50% PD-L1 IHC 22C3
pharmDx
22C3 LDT Ilie et al. 2018 L 120 1.00 1.00
Ilie et al 2017 L 120 1.00 1.00
Røge et al. 2017 L 75 0.93 1.00
Røge et al. 2017 L 75 1.00 1.00
Neuman et al. 2016 L 41 1.00 1.00
Ilie et al. 2018 L 120 1.00 1.00
Røge et al. 2017 L 75 1.00 1.00
Ilie et al 2017 L 120 1.00 1.00
Neuman et al. 2016 L 41 1.00 1.00
Munari et al. 2018 L 183 0.85 0.97
Hendry et al. 2018 L 551 0.84 1.00
50% Ventana PD-L1 (SP263) Ventana PD-L1
(SP142)
Adam et al. 2018 L 41 0.19 1.00
Adam et al. 2018 L 41 0.11 1.00
Adam et al. 2018 L 41 0.19 1.00
Adam et al. 2018 L 41 0.11 1.00
Chan et al. 2018 L 713 0.67 1.00
Fujimoto et al. 2017 L 40 0.33 1.00
Scheel et al. 2016 L 135 0.54 1.00
Soo et al. 2018 L 18 0.33 1.00
Tretiakova et al. 2018 U 161 0.46 0.96
Kim et al. 2017 L 97 0.00 1.00
Cheung et al. 2019 L 54 0.60 1.00
Hendry et al. 2018 L 355 0.33 1.00
Tsao et al. 2018 L 81 0.28 1.00
1% Ventana PD-L1 (SP263) 28-8 LDT Adam et al. 2018 L 41 0.70 1.00
Adam et al. 2018 L 41 0.73 1.00
Adam et al. 2018 L 41 0.76 1.00
Adam et al. 2018 L 41 0.67 0.93
50% Ventana PD-L1 (SP263) 28-8 LDT Adam et al. 2018 L 41 1.00 0.81
Adam et al. 2018 L 41 1.00 0.76
Adam et al. 2018 L 41 0.82 0.67
Adam et al. 2018 L 41 1.00 0.70
1% PD-L1 IHC 22C3
pharmDx
28-8 LDT Adam et al. 2018 L 41 0.66 1.00
Adam et al. 2018 L 41 0.63 1.00
Adam et al. 2018 L 41 0.68 1.00
Adam et al. 2018 L 32 0.70 1.00
Adam et al. 2018 L 32 0.67 1.00
Adam et al. 2018 L 32 0.73 1.00
* L NSCLC, U UC
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tumor proportion score cut-off for PD-L1 IHC 22C3
pharmDx (Table 1 and Table 3). Although the overall
performance of E1L3N laboratory developed tests in the
meta-analysis was not good, E1L3N laboratory developed
tests achieved very high sensitivity and specificity in 3 of 12
comparisons (Fig. 1f–h, Tables 1A and 1B) [18, 27].
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PD-L1 IHC 28-8 pharmDx as reference standard
The highest results were achieved by the Ventana PD-L1
(SP263) assay; it had acceptable accuracy in the meta-
analysis compared to PD-L1 IHC pharm Dx 28-8 at the 1%
cut-off (6/12 tests were clinically acceptable) (Fig. 1h,
Table 1). PD-L1 IHC 22C3 pharmDx did not reach ≥ 90%
for both sensitivity and specificity in the meta-analysis
when compared to PD-L1 IHC pharmDx 28-8 at the 1%
cut-off, although 9/19 individual assay comparisons showed
sensitivity and specificity of ≥ 90% (Fig. 1i, Table 1A and
1B).
Ventana PD-L1 (SP263) as reference standard
No candidate assays achieved required diagnostic accuracy
for either the 1% or the 50% cut-off. Most candidate assays
achieved acceptable specificity, but the sensitivity was too
low for both cut-off points (Tables 1–3).
Discussion
The most dominant result of this meta-analysis is that
properly designed laboratory developed tests that are per-
formed in an individual immunohistochemistry laboratory
(usually a reference laboratory or expert-led laboratory) and
are developed for the same purpose as the relevant com-
parative reference method standard may perform essen-
tially equally to the original Food and Drug Administration-
approved assay, but also generally better than the Food and
Drug Administration-approved companion diagnostics that
were originally developed for different purposes. For
example, to identify patients with non-small cell lung can-
cer for second line therapy with pembrolizumab where PD-
L1 IHC pharmDx 22C3 is not available, the results of our
study indicate that it is more likely that 22C3 or E1L3N
well-developed, fit-for-purpose laboratory developed tests
would identify the same patients as positive and/or negative
as PD-L1 IHC pharmDx 22C3, rather than Ventana PD-L1
(SP263), Ventana PD-L1 (SP142), or PD-L1 IHC pharmDx
28-8, which were developed for different purposes [49–53].
The accuracy of laboratory developed tests varied in our
meta-analysis. 22C3 laboratory developed tests achieved
the best results, with both sensitivity and specificity of
100% in 8/9 studies. E1L3N also showed excellent results,
but in only 3/12 comparisons. Its success in 3 separate
comparisons illustrates that it is possible to develop an
acceptable laboratory developed test with this clone and that
this antibody can be optimized for clinical applications for
which the PD-L1 IHC 22C3 pharmDx was developed. The
successful applications of some of the laboratory developed
tests reinforce the importance of considering the original
purpose of the immunohistochemistry assay, a point
emphasized in the ISIMM and IQN Path series of papers
entitled “Evolution of Quality Assurance for Immunohis-
tochemistry in the Era of Personalized Medicine” [54–57].
It should be pointed out that our meta-analysis indicates that
excellent diagnostic accuracy by laboratory developed tests
can be achieved in some laboratories where the laboratory
developed tests that were included in this study were ori-
ginally developed; it remains to be determined whether the
same laboratory developed tests would perform the same if
more widely tested in different laboratories with different
operators using different equipment. External quality
assurance including inter-laboratory comparisons, as well as
proficiency testing demonstrated that as high as 20–30% or
more of the participating laboratories may produce poor
results with immunohistochemistry laboratory developed
test protocols [58–62]. The success of laboratory developed
tests depends on multiple parameters, including which test
performance characteristics and which tissue tools may
have been used for test development and validation [56, 57].
In the case of predictive PD-L1 immunohistochemistry
assays, recognition and careful definition of the assay pur-
pose according to the 3D approach (Disease, Drug, Diag-
nostic assay) must also be considered, along with
proper selection of the comparative method for determina-
tion of diagnostic accuracy of the newly developed candi-
date test. Several studies have demonstrated that when
laboratories follow this approach, they are able to produce
excellent results [24, 32, 36–38]. Our study and previously
published results do not imply generalizable analytical
robustness of laboratory developed tests, whether de novo
laboratory developed tests or “kit-derived laboratory
developed tests” [6, 32]. When protocols for laboratory
developed tests are shared between laboratories, it is
essential that the adopting laboratory conducts initial tech-
nical validation, which would increase the likelihood of
similar diagnostic accuracy [48, 56]. However, the purpose
Fig. 1 a 22C3 laboratory developed tests (candidate) vs. PD-L1 IHC
pharmDx 22C3 (reference standard) for 1% tumor proportion score
cut-off; b PD-L1 IHC pharmDx 28-8 (candidate) vs. PD-L1 IHC
pharmDx 22C3 (reference standard) for 50% tumor proportion score
cut-off; c Ventana PD-L1 (SP263) (candidate) vs. PD-L1 IHC
pharmDx 22C3 (reference standard) for 50% tumor proportion score
cut-off; d PD-L1 IHC pharmDx 28-8 (candidate) vs. PD-L1 IHC
pharmDx 22C3 (reference standard) for 1% tumor proportion score
cut-off; e Ventana PD-L1 (SP263) (candidate) vs. PD-L1 IHC
pharmDx 22C3 (reference standard) for 1% tumor proportion score
cut-off; f E1L3N laboratory developed tests (candidate) vs. PD-L1
IHC pharmDx 22C3 (reference standard) for 1% tumor proportion
score cut-of; g Ventana PD-L1 (SP263) (candidate) vs. PD-L1 IHC
pharmDx 28-8 (reference standard) for 1% tumor proportion score cut-
off, and h PD-L1 IHC pharmDx 22C3 (candidate) vs. PD-L1 IHC
pharmDx 28-8 (reference standard) for 1% tumor proportion score cut-
off
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of predictive PD-L1 immunohistochemistry assays is not to
demonstrate the best signal-to-noise ratio (“nice” and highly
sensitive results), but to identify patients that are more likely
to benefit from specific drug(s) as demonstrated in clinical
trials. Therefore, consideration of this purpose and direct or
indirect link with the clinical trial results is always required
and it should be considered in test development, test vali-
dation, test maintenance, as well as in test performance
comparison.
As so far there are no tools to measure analytical sensi-
tivity and specificity of immunohistochemistry assays; this
presents a significant problem in assay development,
methodology transfer, and daily monitoring of assay per-
formance, as well as direct comparison of assay calibration.
The lack of tools that could assess analytical sensitivity and
specificity also hinders attempts of immunohistochemistry
protocol standardization/harmonization for the PD-L1
assays; without such tools it is not possible to determine
the desirable range of analytical sensitivity and specificity
of relevance for diagnostic accuracy for any of the PD-L1
assays. This is one cause that we can identify as a potential
source of the discrepancy between previously published
works that suggested analytical interchangeability of the
several Food and Drug Administration-approved PD-L1
assays, but did not necessarily lead to interchangeability
based on calculated diagnostic accuracy as shown in
our study.
The Ventana PD-L1 (SP263) assay had very high diag-
nostic sensitivity against all other Food and Drug
Administration-approved PD-L1 assays, but its diagnostic
specificity was consequently lower. Although several of the
studies included in this meta-analysis demonstrated sub-
stantial analytical similarity between PD-L1 IHC 22C3
pharmDx, PD-L1 IHC 28-8 pharmDx, and Ventana PD-L1
(SP263), our cumulative results suggest that the diagnostic
sensitivity of these various assays (and indirectly their
analytical sensitivity) is ordered as follows: PD-L1 IHC
22C3 pharmDx < PD-L1 IHC 28-8 pharmDx < Ventana
PD-L1 (SP263).
The results of this meta-analysis confirm previous
observations that the Ventana PD-L1 (SP142) assay’s ana-
lytical sensitivity is significantly lower than that of the three
other Food and Drug Administration-approved PD-L1
assays and that the diagnostic sensitivity of Ventana PD-L1
(SP142) against PD-L1 IHC 22C3 pharmDx, PD-L1 IHC
28-8 pharmDx, and Ventana PD-L1 (SP263) assays is
prohibitively low for both the 1% and the 50% tumor
proportion score in non-small cell lung cancer and other
tumor models.
Several investigators have evaluated the so-called
“interchangeability” of PD-L1 immunohistochemistry
assays. The term “interchangeability” has also been used
widely by the pharmacological industry to designate drugs
that have demonstrated the following characteristics: same
amount of the same active ingredients, comparable phar-
macokinetics, same clinically significant formulation char-
acteristics, and to be administered in the same way as the
drug prescribed [63]. Basically, interchangeable drugs have
the same safety profile and therapeutic effectiveness, as
demonstrated in clinical trials [64, 65]. To apply this term to
an immunohistochemistry predictive assay, the manu-
facturer of the assay, be it industry for a companion/com-
plementary diagnostic or a clinical immunohistochemistry
laboratory for an laboratory developed test, would need to
prove that the alternative assay will produce the same
clinical outcomes. Since none of the assay comparisons
were performed in the setting of a prospective clinical trial,
this type of evidence is not available for PD-L1 immuno-
histochemistry assays and therefore, none can be deemed
“interchangeable” with another in this same sense of the
word. In addition, candidate assays and comparative assays
cannot interchange their positions for the purpose of cal-
culations without consequences [11]. If “interchangeability”
would be defined as achieving ≥90% sensitivity and spe-
cificity for both the 1% and the 50% tumor proportion score
cut-off points, none of the studies in this meta-analysis
demonstrated “interchangeability” of the Food and Drug
Administration-approved assays PD-L1 IHC 22C3
pharmDx, PD-L1 IHC 28-8 pharmDx, Ventana PD-L1
(SP142), or Ventana PD-L1 (SP263) for each other.
Although they cannot be designated as “interchange-
able”, the diagnostic accuracy of assays for a specific
clinical purpose may be compared. In this manner,
the comparison indirectly generates results that can
be used to justify clinical usage of assays other than those
included in the clinical trials. We employed ≥90% diag-
nostic sensitivity and ≥90% diagnostic specificity because
these values are often used in other settings, including
performance of immunohistochemistry assays [66–68].
While it is reasonable that a candidate assay should
have at least 90% diagnostic sensitivity, it is unclear
whether the required diagnostic specificity should be at
the same level, or whether lower specificity could also be
clinically acceptable. From the perspective of patient
safety, lower diagnostic specificity could potentially be
acceptable for those indications/purposes where clinical
trials demonstrated that progression free survival, overall
survival, and adverse effects in patients with PD-L1-
negative tumors treated by immunotherapy are at least
comparable if not better to that of conventional
chemotherapy.
The strengths of this meta-analysis are the focus on
diagnostic accuracy, fit-for-purpose approach, and the
access to previously unpublished data from a large number
of studies, which all resulted in pooled PD-L1 assay com-
parison in a way that has not been done before.
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The most significant limitation is that this is a meta-
analysis of test comparisons where designated reference
standards are other tests rather than clinical outcomes.
However, to complete a meta-analysis with clinical out-
comes may not be possible for many years, if ever. Other
limitations of this meta-analysis are that only two cut-off
points were assessed (1% and 50%), no assessment for
readout that includes inflammatory cells was included, the
impact of pathologists’ readout as potential source of var-
iation between the studies was not assessed, and it is
somewhat uncertain how the results apply to tumors other
than non-small cell lung cancer due to the smaller number
of such studies.
Conclusions
The complexity of the PD-L1 immunohistochemistry test-
ing cannot be safely simplified without consideration of the
original test purpose. Determination of the diagnostic
accuracy and indirect clinical validation of a candidate
assay can be achieved by comparing the results of that assay
to a previously designated reference standard assay, when
direct access to clinical trial data or clinical outcomes is not
possible.
Our meta-analysis indicates that
1) Well-designed, fit-for-purpose PD-L1 laboratory devel-
oped test candidate assays may achieve higher accuracy
than PD-L1 Food and Drug Administration-approved kits
that were designed and approved for a different purpose,
when both are compared to an appropriate designated
reference standard;
2) More candidate assays achieved ≥ 90% sensitivity and
specificity for 50% tumor proportion score cut-off than for
1% tumor proportion score cut-off;
3) The overall diagnostic sensitivity and specificity
analyses indicates that the relative analytical sensitivities of
the Food and Drug Administration-approved kits for tumor
cell scoring, most specifically in non-small cell lung cancer,
are as follows: Ventana PD-L1 (SP142) << PD-L1 IHC
22C3 pharmDx < PD-L1 IHC 28-8 pharmDx < Ventana
PD-L1 (SP263).
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